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ABSTRACT 
Background: There are many causes of intestinal complication in premature infants, ranging 
from structural issues to dysbiosis. This study aims to investigate the effect of an Artificial 
Placenta (AP) utilizing extracorporeal membrane oxygenation (ECMO) on intestinal structure 
and injury.   
Methods: Small intestine from 3 groups of premature lambs (n=5 from each) was analyzed. 
These groups included: lambs of 118-121 days estimated gestational age (EGA) delivered via 
caesarian section and placed on the AP (AP group); lambs of 115-121 days EGA and 125-131 
days EGA delivered via caesarian section and immediately sacrificed (early tissue control, ETC 
group; late tissue control, LTC group, respectively). Post necropsy, jejunal samples were 
formalin fixed and stained for analysis with H&E, Ki-67, and lysozyme. From H&E slides, crypt 
depth (CD), villus height (VH), and CD:VH ratio were analyzed. From Ki-67 slides, cell 
proliferation was analyzed, and from lysozyme slides paneth cell counts were taken to determine 
small intestine response to injury. In addition, injury scores evaluating epithelial injury, 
congestion, villus atrophy, and inflammation were determined.    
Results: CD, VH, and CD:VH ratio were similar between the three groups (p>0.05). AP lambs 
demonstrated more enterocyte proliferation (95.7+21.8) than ETC lambs (49.4+23.4; p=0.003) 
and LTC lambs (66.1+11.8; p=0.04), and more Paneth cells (81.7+17.5) than ETC lambs 
(41.6+7.0; p=0.0005) and LTC lambs (40.7+8.2, p=0.0004).  There was more epithelial injury 
and congestion seen in AP lambs compared to ETC and LTC lambs, however the results were 
not significant (p=0.05; p=0.07, respectively).  No villus atrophy or inflammation was present in 
any group. 
Conclusion: Results support that the AP preserves small intestine architecture and promotes 
cellular turnover. Small intestine injury on the AP was minimal. Future studies will focus on 
obtaining a profile of intestinal bacteria to investigate differences in microbiota composition 
between different AP lambs and AP and term lambs.  
 
INTRODUCTION 
Immune system of the gastrointestinal tract  
 It is easy to consider the immune system and bacteria as separate, but in actuality, a huge 
proportion of the immune system is located in the gastrointestinal (GI) tract. The GI tract is 
where bacteria and the immune system meet. Defense of the GI system includes the adaptive and 
innate immune systems as well as the protective benefits from the gut microbiota. 
Induction of the gut adaptive immune response involves the usual activation of B and T 
cells by antigen presenting cells and the resulting effector functions of these adaptive cells. 
Secretory IgA (sIgA) antibodies are the major humoral defense factor of gut immunity. These 
antibodies serve as a main line of defense in protecting the intestinal epithelium from enteric 
toxins and pathogenic microorganisms. This is done through immune exclusion, promoting the 
clearance of antigens and pathogens from the intestinal lumen by blocking their access to gut 
epithelial receptors, entrapping them in mucous, and facilitating their removal by peristaltic and 
mucocilliary means1. Meanwhile, regulatory T cells have also been shown to play an important 
role in the cellular defense and response to intestinal antigens2.    
 Induction of the gut innate defenses starts with physical and chemical barriers and 
extends to secreted antimicrobial peptides (AMPs). Physical barriers include the epithelial cell 
layer and actions of gut motility, and chemical barriers include mucous, bile, gastric acid, and 
pancreatic enzymes3. AMPs mostly come into play once a pathogen has breached these barriers 
and invaded the mucosal membrane. When this happens, the intestinal cells recognize pathogen 
associated molecular patterns (PAMPs) with pattern recognition receptors (PRRs)4 such as Toll-
like receptors (TLRs); when a PAMP binds a PRR, AMPs including cathelicidins, defensins, and 
lysozymes are secreted5.     
 Defensins are small, cationic, antimicrobial peptides. They are found in high 
concentrations in the granules of phagocytes as well as in Paneth cells, specialized innate 
immune cells of the small intestine. Defensins have the ability to kill and inactivate a wide range 
of microbial pathogens including gram-negative and gram-positive bacteria, fungi, protozoa, and 
viruses. Their cationic and amphipathic nature allows them to easily cross negatively charged 
microbial membranes. Cathelicidins are a class of AMPs that have varying bactericidal potential. 
They are synthesized as larger precursor molecules with a variant C-terminal antimicrobial 
functional domain. The heterogeneity of the C-terminal is what allows for the wide range of 
cathelicidin activity, and there is a wide overlap in activity within the families of cathelicidins. 
Cathelicidin families can also be chemotactic for innate immune cells such as monocytes and 
neutrophils. Lysozyme is an extremely potent AMP. Lysozyme expression has been noted in a 
variety of cell and tissue types, including in the paneth cells of the small intestinal crypts. In the 
small intestine, lysozyme is found to be secreted into the crypts; it works to decrease the integrity 
of pathogens’ cell walls, thus causing death of the pathogen5.  
 
Paneth Cells  
 As seen above, paneth cells are an important component of the GI innate immune 
response. They are located in the small intestine crypts of Lieberkühn. Their apical granules 
point towards the intestinal lumen, and synthesize and secrete AMPs and various proteins. They 
are key in modulating and mediating host-microbe interactions, including the homeostatic 
balance with the colonizing microbiota and the innate immune protection from pathogens. They 
also secrete factors that have been known to help sustain and modulate the progenitor cells and 
epithelial stem cells of the crypts and play a role in revitalizing the small intestine epithelium.  
Paneth cell dysfunction can contribute to the pathogenesis of inflammatory intestinal 
diseases6. A study by Nita H Salzman demonstrated that paneth cell defensins are actually able to 
regulate the composition of the intestinal bacterial microbiome. She noted defensin-dependent 
reciprocal shifts in the dominant bacterial species of the small intestine without changes in 
overall bacterial numbers. This further supports the importance of paneth cells and their 
secretory components in maintaining intestinal homeostasis7.    
 
Host microbiota function in defense  
 Beyond the immune system, immunity is also provided by the host microbiota. The 
microbiota is the name given to the complex and dynamic population of microorganisms that 
inhabit the gut. Soon after birth, organisms establish their own unique gut microbiota determined 
by their maternal flora as well as genetic and epigenetic factors3. Beyond these initial factors, 
diet is also main driver in shaping the microbiota of the gut across an organism’s lifetime. The 
microbiota has co-evolved with their host to form an intricate and mutually beneficial 
relationship, so much so that these mutualistic intestinal bacteria play a crucial role in 
maintaining immune and metabolic homeostasis and protecting the gut by outcompeting 
pathogens. In addition, the microbiota also offers benefits to the host through physiological 
functions such as strengthening gut integrity, shaping the intestinal epithelium, and harvesting 
energy. In fact, altered composition of gut bacteria (dysbiosis) has been associated with the 
pathogenesis of many inflammatory diseases and infections8. This is why so many antibiotics 
have gastrointestinal complications as side effects; they drastically alter the gut microbiota. The 
intestinal microbiota is extremely important for normal gastrointestinal development, protection, 
and function.  
 
Necrotizing enterocolitis 
 When any aspect of gut immunity is compromised, aberrant colonization by pathogenic 
bacteria (i.e. infection) can lead to devastating effects. One such infection, which targets 
premature infants, is necrotizing enterocolitis (NEC). Just hearing this term strikes fear in the 
hearts of preemie parents, as NEC is one of the most catastrophic comorbidities associated with 
prematurity. It is a devastating gastrointestinal disease that is associated with severe sepsis, 
intestinal perforation, and significant morbidity and mortality9. Though the pathogenesis is still 
not fully understood and is believed to be multifactorial, dysbiosis by way of disruption or delay 
of acquisition of commensal microbiota has been implicated as a key risk factor in the 
pathogenesis of NEC. Conversely a beneficial complement of commensal intestinal microbiota 
has been found to protect the neonatal gut from inflammation and injury. Nowadays, 
interventions aimed at providing or restoring a healthy microbiota, such as probiotic therapy, are 
extremely promising treatments to prevent NEC. Shifting the balance of intestinal bacterial from 
pathogenic to protective can protect the gut from the inflammation and injury characteristic of 
NEC. Studying and better understanding NEC is incredibly important as 20-30% of infants who 
develop NEC will succumb to it10. The biggest risk factor for NEC is prematurity and an 
immature gastrointestinal tract; the disease disproportionately affects premature and extremely 
low birth weight (ELBW) infants.  
 
Prematurity  
Every year an estimated 15 million babies, around 1 in every 10, are born prematurely 
(less than 37 weeks gestational age) in the US. Being born prematurely usually comes with a 
host of complications that follow the child for their entire life, if they survive infancy; preterm 
birth complications are the leading cause of death for children under 5 years of age, and 
accounted for nearly 1 million deaths in 201511. Among the preterm babies delivered, those born 
at less than 28 weeks, the micro-preemies, face the highest rates of mortality and complications.  
Most of these babies are born at ELBW (weighing less than 2 pounds, 3 ounces) and 
almost all require treatment with surfactant, oxygen, and mechanical ventilation to help them 
breathe. In addition to their lungs and gastrointestinal tract, other organs and systems are 
underdeveloped, leading multiple complications outside of simply breathing and NEC. ELBW 
newborns can face neurological complications that extend from an immature renal system due to 
sodium retention, as their immature kidneys’ cannot concentrate urine well. They are also 
especially susceptible to retinopathy of prematurity (ROP), a disease brought on by high oxygen 
levels that can cause retinal detachment and blindness if not treated. In addition, they are unable 
regulate their own temperature, and spend weeks in temperature controlled incubators to combat 
hypothermia12.  
For babies born under 24 weeks, the prognosis is most grim. Outcomes research puts 
survival for babies born at 24 weeks at 56%, 23 weeks at a mere 26%, and 22 weeks at only 
5%13. Furthermore, most micro-preemies face one if not many of the above mentioned health 
complications because of how underdeveloped their organs systems are and more often than not, 
these complications contribute to, if not directly cause, death. For those babies lucky enough to 
survive their premature birth, most of these complications do not simply disappear once they 
leave the NICU, and often other complications such as cerebral palsy, emotional and behavioral 
complications, and neurological delays can only be uncovered as the child grows and misses 
developmental milestones.  
Due to severely underdeveloped lungs, premature babies are often left with 
bronchopulmonary dysplasia (BPD), a chronic lung disease that causes abnormal lung growth 
and inflammation. For some children, over time the lungs can heal some, but most face asthma-
like symptoms throughout their lives. Babies who survive NEC in the hospital oftentimes have to 
undergo surgery to remove the infected parts of their intestines, and as a result of this shortening 
of their GI tract, can face issues with proper nutrient absorption from the food they eat. 
Furthermore, scarring from the NEC can lead to intestinal blockages and associated pain. Many 
babies who develop ROP, too, must undergo surgery in a timely fashion to correct the problem 
or face lifetime blindness. Still, even with proper medical treatment and surgical intervention, 
many ROP babies face vision problems as they age14,15. Overall, preterm birth accounts for the 
leading cause of death for children under the age of 511.  
 
Mechanical ventilation and associated complications  
The current standard of care for premature babies with severe respiratory distress 
syndrome (SRDS) is intubation followed by invasive mechanical ventilation. This allows for 
premature babies who cannot sufficiently support themselves breathing on their own to still 
receive oxygen and discard carbon dioxide16. In regular breathing, the inhalation process is 
active. The diaphragm contracts, moving downwards and increasing the space in the chest cavity. 
This allows for the lungs to expand with air. The exhalation process is passive. The diaphragm 
relaxes and moves upwards; this tightening of space forces air out of the lungs17. Invasive 
ventilation works by way of positive pressure. Similar to the active inhalation process, it blows 
air, with or without extra oxygen depending on the baby’s needs, into the airways and lungs. 
However, on a ventilator, the exhalation process is also active, as the ventilator takes over this 
part of breathing as well18. Since the introduction of invasive mechanical ventilation as standard 
of care for premature babies, mortality from SRDS has decreased from 268 in every 100,000 
births in 1971 to 14.7 in every 100,000 births in 200819.  
However, while invasive mechanical ventilation has saved the lives of countless 
newborns with SRDS, it comes with many complications of it’s own. Mechanically, the small 
size of the patients results in challenges with high respiratory rate, rapidly changing lung 
compliance, highly compliant chest wall, short inspiratory time, and small tidal volumes. In 
addition, as literature has shown associated tracheal injury using cuffed endotracheal (ET) 
tubes20, premature infants are intubated with uncuffed ET tubes, and are thus victim of air leaks. 
These air leaks coupled with incredibly small tidal volumes (sometimes as low as 2-3 mL) makes 
detection of flow and accurate measurement of both inspiratory and expiratory tidal volume 
extremely complex16.  
Besides mechanical difficulties, this kind of positive pressure ventilation can actually 
contribute to the health complications premature infants face, such as BPD21. This disorder is 
primarily seen in ELBW infants and micro preemies requiring ventilator support and 
supplemental oxygen, as oftentimes, their frail and immature lungs simply cannot handle the 
positive pressure force of the ventilator. These patients experience decreased alveolarization of 
pulmonary tissue and small airway diseases, as well as inflammation and fibrosis, at a reported 
rate reported between 30 and 40%22.  
Other complications of mechanical ventilation include intraventricular hemorrhage 
(IVH), again, due to the positive pressure being forced into the baby’s system, and NEC. In fact, 
a study done by Carter and Holditch-Davis showed length of mechanical ventilation as a primary 
predictor of NEC in preterm infants. Infants who required mechanical ventilation during the 
neonatal period were 13 times more likely to develop NEC23, and as the number of days an infant 
spent on a mechanical ventilator increased, so did their risk of developing NEC24. 
 
The Artificial Placenta  
Currently, mechanical ventilation can be seen as the lesser of two evils, preferable to 
death by SRDS but not the solution. What premature infants really need is some sort of 
technology that can simulate the intra-uterine environment, thus allowing for continuation of 
critical organ growth and development despite a newborn’s early arrival. The artificial placenta 
(AP) is exactly this kind of technology. The AP uses extracorporeal membrane oxygenation 
(ECMO) to provide the premature baby with adequate oxygenation and carbon dioxide removal 
without their underdeveloped bodies needing to do any of the hard work. An ECMO circuit 
consists of cannulas placed into major blood vessels (an artery and vein for AV-ECMO or two 
veins for VV-ECMO) that are connected via silicon tubing to a pump and oxygenator. Based on 
how the circuit is hooked up, ECMO can act as either a patient’s lungs (in the case of VV 
ECMO) or their heart and lungs (AV-ECMO). When a patient is on ECMO, blood drains out of 
their body and is pumped through an oxygenator. Within the fibers of the oxygenator, oxygen is 
diffused into the blood and carbon dioxide out of the blood. This blood is then circulated back 
into the body25. This is life saving technology.  
The AP functions by utilizing VV-ECMO while still maintaining fetal circulation26,27. 
Fetal circulation differs from typical circulation in that in-utero, the placenta does the work the 
developing lungs are supposed to do. Furthermore, fetuses have three shunts, the ductus venosus, 
ductus arteriosus, and foramen ovale, which direct blood around the lungs and liver. In a healthy 
newborn, fetal circulation ceases when the baby is born and takes their first breaths of air. 
However, for a premature newborn on the AP, the end goal is to “trick” the baby into thinking 
they are still in-utero, so prostaglandins are given intravenously (IV) and the oxygen saturation 
of the blood is left low to keep the ductus arteriosus patent. The ductus arteriosus connects the 
pulmonary artery to the descending aorta and allows blood from the right ventricle to bypass the 
lungs, allowing them to develop without risk of congestion from too much blood flow28. 
The goal of the AP is to be a passive environment that provides extremely premature 
newborns with the support they need to grow and develop as they would in-utero. In addition, as 
the AP doesn’t require invasive mechanical ventilation or any sort of positive pressure, 
associated risks such as BPD and IVH become non-issues. The hope is that this device will also 
lead to a decrease in cases of NEC. The AP is supposed to both decrease morbidity and mortality 
associated with preterm birth and increase quality of life for premature newborns. This being 
said, investigation into the device’s impact on all organs must be done to make sure this is 
actually the case. This investigation will start with the small intestine.  
This study aimed to understand small intestine growth and injury of extremely premature 
lambs on the AP in order to better comprehend why the premature gut is so much more 
susceptible to NEC. This analysis provides a structural understanding by specifically evaluating 
mucosal architecture, cellular proliferation, injury, and response to injury. We hypothesized that 
small intestine architecture would be preserved during AP support and injury and response 
would be comparable to tissue controls. The hope is that a better understanding of structural 
development on the AP will lead to future microbiological studies of the lambs’ small intestine 
to understand the effects of the AP on microbiota development. Together, this structural 
investigation and microbiological survey should provide a better understanding of NEC 
susceptibility in premature infants.  
  
METHODS29 
The experimental procedure was performed in an ovine model following protocol 
approval by the University of Michigan Institutional Animal Care and Use Committee (IACUC) 
(protocol 00007211).  All sheep used for the experiment were treated in compliance with the 
Guide for Care and Use of Laboratory Animals, 8th edition. 
Lambs used for the experiment were divided into three groups: Artificial Placenta (AP) 
Group, Early Tissue Control (ETC), and Late Tissue Control (LTC). Age and weight of each 
lamb were recorded. 
 
Experimental Groups  
AP Group 
Premature lambs of 116-121 days EGA (term = 145; n =5) were delivered via C-Section.  
10-14Fr cannulas (Terumo: Ann Arbor, MI) were placed in the jugular vein (drainage) and 
umbilical vein (reinfusion). The circuit was completed with ¼” tubing (Tygon: Lima, OH), a 
collapsible-tubing roller pump (MC3: Ann Arbor, MI), and oxygenator/heat exchanger (either 
Medos HiLite, Xenios: Heilbronn, Germany or Capiox Baby Rx, Terumo, Ann Arbor, MI; 
Figure 1).  Veno-venal extracorporeal life support (VV-ECLS) was initiated and the lambs were 
monitored closely.  A 5 Fr arterial line (Covidien-Medtronic: Minneapolis, MN) was placed into 
the umbilical artery for hemodynamic monitoring and arterial blood gas (ABG) blood draws.  
The second umbilical vein was cannulated with a 5 Fr triple lumen venous line (Covidien-
Medtronic: Minneapolis, MN) for intravenous fluid, TPN, heparin sulfate (SAGENT, 
Schaumburg, IL) (100 U/hr, titrated to a goal activated clotting time (ACT) of 200-250 seconds), 
and Prostaglandin E1 (Pfizer, New York, NY) (0.2mcg/kg/min) infusion to maintain ductal 
patency.  The lambs were intubated and lungs were filled with fluid (amniotic fluid, Ringer’s 
Lactate, or perfluorodecalin [Origen: Austin, TX]).  
All lambs were supported on TPN infused via the umbilical vein.  The TPN (ExactMix, 
Baxter Healthcare Corporation, Englewood, CO.  Baxter International Inc. Supplied by the 
University of Michigan HomeMed- Home Infusion Pharmacy) was made with a standard 
composition including: Amino Acids (15%) (16 GM); Dextrose (45 GM); IntraLipds (80 ML); 
and electrolytes (Sodium Phosphate (5.4 MM); Potassium Chloride (8.1 MEQ); Magnesium 
Sulfate (1.6 MEQ); and Calcium Gluconate (1 MEQ)) in 400 mL volume administered at a rate 
of 5 mL/kg/hr.  All AP lambs remained nil per os (NPO) during support.  Hemodynamics, urine 
output, and bowel movements were monitored.  All lambs were given prophylactic intravenous 
antibiotics (piperacillin-tazobactam [Hospira Inc., Lake Forest, IL]) and antifungals (fluconazole 
[SAGENT, Schaumburg, IL]) to prevent infection.  Solumedrol (Pfizer, New York, NY) 0.63 
mg/kg was given every 12 hours to prevent hypocortisolemia.  Diazepam (Hospira Inc., Lake 
Forest, IL) 2.5mg and Buprenorphine (Parr Inc., Spring Valley, NJ) 0.3mg were used sparingly 
for pain or agitation.  In cases of volume-resistant hypotension, vasopressors (norepinephrine 
(Claris LifeSciences Inc., North Brunswick, NJ), epinephrine (Hospira Inc., Lake Forest, IL), or 
dopamine (Baxter, Deerfield, IL)) were used to maintain a (mean arterial pressure) MAP >40 
mmHg.  AP support was continued for 7-10 days, and then the animals were euthanized. 
 
Tissue Control Groups 
Early and Late Tissue Controls (ETC; n=5 and LTC; n=5) were delivered at 115-121 and 
125-131 days respectively. They were immediately sacrificed.  
 
Necropsy, Tissue Preparation, and Histological Analysis 
After sacrifice, the small intestine was removed en bloc and formalin-fixed.  Standardized 
2 cm longitudinal sections of jejunum were taken from 6 cm distal to the duodeno-jejunal 
junction to be used for mucosal measurements and staining.  Sections from proximal, mid, and 
distal jejunum, terminal ileum, and cecum were also harvested for injury scoring.  All samples 
were sectioned 3-5 µm thick.  Slides were stained with Hematoxylin and Eosin (H&E), Ki-67, 
and Lysozyme, then digitized and reviewed via ImageScope (Leica Biosystems Imaging, Inc 
2016, USA).  Cell counts and measurements were summed for each sample then averaged for 
each group.  Injury scores were marked as present or absent in the 5 anatomic locations for each 
animal.  All measurements were done in a blinded fashion. 
 
Histological Measurements 
H&E Stain to Evaluate GI Mucosa Crypt Depth and Villus Height   
Slides were stained with H&E (Fischer Scientific, Pittsburgh, PA).  After review of each 
slide using ImageScope, Crypt depth (CD), villus height (VH), and CD:VH ratio (12/slide) were 
measured in micrometers and averaged.  Measurements of CD and VH were only taken for those 
in which the plane of sectioning ran vertically from the tip of the villus to the base of the 
adjacent crypt.  VH was measured from tip of villus to the crypt mouth, and CD was measured 
from crypt mouth.  For each slide, 12 of the most representative villi were used for measurement 
and the corresponding 12 crypts.  
 
Ki67Antibody Stain to Measure GI Epithelial Cell Proliferation  
Slides stained with Ki67 antibody (Abcam, Cambridge, MA) were used to evaluate GI 
enterocyte proliferation.  50 crypts from 5 different places of 10 consecutive crypts were 
reviewed per slide, and all the cells in the crypts stained dark brown with Ki67 were counted per 
slide and averaged.  Measurements were taken and compared between groups.  
 
GI Mucosal Injury Severity Scores:  
H&E-stained slides were reviewed and scored by experienced pediatric pathologist, Dr. 
Raja Rabah, who was blinded to the groups.  Intestinal injury scores were measured using 
presence of inflammation, epithelial injury, congestion, hemorrhage, and villus atrophy.  
Presence was measured as 1 and absence as 0.  Since there was absence of inflammation, villus 
atrophy, and only minor hemorrhage among the groups, only epithelial injury and congestion 
were compared between groups.  
 
Paneth Cells Stained with Lysozyme Antibody to Measure Immune Response 
Proximal jejunal sections were stained with Lysozyme antibody (Invitrogen, IL, USA).  
Images with clearly defined Paneth cells within the crypts were included in the analysis.  Paneth 
cell counts were averaged per slide.  Those values were then averaged per animal in each group 
and compared between groups.  
 
Statistical Analysis 
The Graphpad Prism version 7.0 statistical software (GraphPad Software Inc, 2017, 
USA) and ANOVA with post-hoc Tukey’s Test was used to compare groups with Ki-67 stain, 
Lysozyme stain, and CD, VH, and CD:VH Ratio.  IBM Corp. Released 2013. IBM SPSS 
Statistics, Version 22.0 (Armonk, NY), Fischer Exact Test was used to compare presence of 
injury score for each anatomic GI location for epithelial injury and congestion.  P<0.05 defined 
statistical significance.  
 
RESULTS29 
GI Mucosal Development in Premature Lambs (H&E Stain) 
The objective of staining the GI slides with H&E was to evaluate GI mucosal 
development. There was no significant difference between CD in the small intestines of ETC 
(68.5+7.3) and LTC (77.2+8.2) with p=0.18.  Although the CD in AP small intestine (77.5+5.9) 
was not statistically different than ETC (p=0.16) and LTC (p=0.99), there was an increasing 
trend of AP CD similar to that of the LTC group.  VH of the AP Group (315.6+70.4) was 
comparable to ETC (314.9+7.3; p=0.99) and LTC (297.9+32.6; p=0.88), without differences 
compared to ETC and LTC VH (p=0.89).  Similarities were also found between the AP CD:VH 
Ratio (4.1+0.9) compared to ETC (4.7+1.4; p=0.58) and LTC (3.9+0.6; p=0.96).  No differences 
were found between CD:VH ratio of ETC and LTC (p=0.42) (Figure 2).  
 
GI Proliferation in Premature Lambs (Ki67 Stain) 
The objective of staining the GI slides with Ki-67 was to evaluate enterocyte proliferation 
in the GI tract. Significantly more enterocyte proliferation was found in the AP group 
(95.7+21.8) when compared to ETC (49.4+23.4; p=0.003) and LTC (66.1+11.8; p=0.04).  There 
were no significant differences between both tissue control groups (p=0.35) (Figure 3).  
 
GI Paneth Cell Count in Premature Lambs (Lysozyme Stain) 
The objective of staining the GI slides with lysozyme was to obtain paneth cell counts in 
order to determine intestinal response to injury. There were significantly more positively stained 
Paneth cells in the AP Group (81.7+17.5) when compared to both ETC (41.6+7.0; p=0.0005) and 
LTC (40.7+8.2; p=0.0004).  The number of lysozyme stained Paneth cells were similar between 
the ETC (41.6+7.0) and the LTC (40.7+8.2), p=0.99.  
 
GI Injury Severity in Premature Lambs (H&E Stain) 
The objective of analyzing GI injury was to determine injury severity between the AP, 
ETC, and LTC lambs. There was no evidence of inflammation or villus atrophy in any of the 
three groups (AP, ETC, LTC).  One AP animal exhibited presence of hemorrhage in the mid 
jejunum and colon, but otherwise there was no hemorrhage found in any other animals or 
anatomic locations.  Epithelial injury was present in ETC and AP groups, while congestion was 
present in LTC and AP groups. The distal jejunum showed more epithelial injury and congestion 
in the AP group, however these numbers were not statistically significant. There was, however, a 
trend towards significance  (p=0.05; p=0.07, respectively). There was otherwise no statistical 
difference between groups (Table 1).  
 DISCUSSION 
 This study aimed to investigate small intestine growth and development as well as 
intestinal injury and response to injury. The data showed a protective effect from the AP on 
intestinal growth and development, as lambs supported on the AP maintained intestinal structure 
and integrity. This was evidenced by CD, VH, and CD:VH ratio. Overall, the small intestine of 
AP supported lambs showed minimal evidence of injury. AP lambs also showed an appropriate 
and adequate response to injury evidenced by increased cell proliferation and paneth cell counts.   
 CD, VH, and CD:VH ratio are literature-supported measures of intestinal growth and 
development. As a fetus develops in utero, villus length and crypt depth increase, finally 
reaching maturity around term. Part of this increase is thought to be due to increase in cell 
proliferation and slower rates of cell shedding when compared to proliferation30. The data from 
this study showed no significant difference in CD between the AP, ETC, and LTC groups, 
supporting that small intestine structure is preserved in lambs on the AP. Additionally, though 
the numbers did not reflect true significance, CD of AP lambs increased towards CD of LTC 
lambs, providing evidence that the AP might actually aid intestinal growth and development. VH 
and CD:VH ratios of AP lambs were similar to both ETC and LTC lambs.  Furthermore, the 
increase in cell proliferation and CD in AP supported lambs is consistent with the in utero 
increase in CD and VH, further supporting the AP’s clinical relevance as a simulation of the 
intra-uterine environment.  
 Apart from being evidence of CD and VH increase with intra-uterine development of the 
fetus, increase in cell proliferation is also seen as a response to injury31. Paneth cells, too have 
been known to be markers of both intestinal development32 and an injury/inflammation 
response33. Paneth cells first appear in the first trimester of pregnancy, mature by the age of 
viability (22-24 weeks), and then increase in number by full term gestation32. Thus, they increase 
and mature as the fetus develops. It is these mature paneth cells that then work as markers of 
inflammation and injury. Upon invasion of the intestines by pathogenic bacteria and fungi, 
paneth cells release AMPs, lysozyme, and growth factors into the lumen of the intestines in an 
attempt to protect and preserve the intestinal epithelia33. In pathogenic intestinal infections such 
as NEC, after the acute phase infection, studies have shown that paneth cell numbers decrease34. 
However, after recovery from the inflammation, paneth cells are upregulated35. Thus, an increase 
in paneth cells is evidence of proper response to intestinal injury. The increased cell proliferation 
and increased paneth cell counts seen in the AP supported lambs provide evidence of both 
intestinal development and an appropriately protective response to injury.  
 Consistent with the increased proliferation and paneth cell counts, the small intestine 
tissue of AP supported lambs did show minor evidence of injury. This injury can be classified as 
minor because despite the injury, intestinal structure was preserved, as evidenced by CD and VH 
measurements. To determine small intestine injury, this study investigated inflammation, villus 
atrophy, hemorrhage, congestion, and epithelial injury, paralleling the variables of epithelial cell 
inflammation, edema, necrosis, and hemorrhage used in established studies36. Regardless of 
group, none of the lambs’ intestines showed evidence of inflammation or villus atrophy. There 
was minimal hemorrhage noted in the mid-jejunum and colon of one AP supported lamb; all 
other lambs from all groups showed no hemorrhage anywhere in the small intestine. There was, 
however, noted congestion and epithelial injury in the distal jejunum in AP supported lambs; this 
might suggest that this area of the intestine is more susceptible to injury, however further studies 
will need to be performed to make any definitive conclusions.   
 Small intestine injury in AP supported lambs can arise from a variety of factors including 
the administration of vasopressor medications, hypoperfusion, and lack of enteral feeds.  
Two of the 5 AP lambs were supported on vasopressor medications for anywhere from 3-
6 days. Vasopressor medications can increase peripheral vascular resistance. As a result, they can 
cause intestinal hypoperfusion, as they are oftentimes associated with a decrease in regional 
blood flow, which can also lead decreased splanchnic blood flow. Impaired blood flow to 
splanchnic organs including the small intestine can cause injury such as intestinal necrosis, renal 
insufficiency, and gastric ulceration37. Furthermore, the tissue damage that results from this 
reduced perfusion of the small intestine can cause damage to and disruption of the mucosal 
barrier, thus allowing bacteria in the GI tract access to systemic circulation38. This can result in 
severe infection leading to systemic sepsis39. Though no such evidence was seen in this study, 
this is something to be considered with the clinical translation of the AP, especially given the 
increased susceptibility of premature infants to infection. 
Hypoperfusion of the intestines could also be due to the actual AP device. The AP 
utilizes ECLS technology, wherein the blood is oxygenated outside of the body. Normally, under 
rest conditions, the intestines receive about 20% of cardiac output and anywhere from 20-35% of 
systemic oxygen delivery. However, blood flow and oxygen supply to the GI tract is reduced in 
critical conditions to maintain perfusion to the brain and heart muscle39. When the blood pressure 
of a patient on ECLS drops, similar effects occur, and many of the AP supported lambs showed 
intermittently low MAPs as low as mid 20s (target range of MAP in this study was 40-50).  
Most notably, however, is the fact that all the AP lambs were maintained NPO, getting 
their nutrients solely from TPN. In utero, the human fetus is constantly inhaling and swallowing 
amniotic fluid, infesting anywhere from 750-1000 mL daily. Meanwhile, a sheep fetus ingests 
anywhere from 100-1000 mL daily40. Established studies have shown that swallowing this fluid 
can have a protective effect on the intestines, and in fact contributes to increased mucosal 
development. Conversely, a lack of fluid leads to decreased birth weight and abnormal intestinal 
structure, including decreased intestinal mucosal thickening, and decreased VH and villus cell 
density41. This just goes to show that liquid enteral nutrition provides a positive effect to 
developing intestines. Further supporting this point is the fact that premature human infants in 
the NICU are given minimal amounts of breast milk enterally in an effort to prime their GI tracts. 
Studies have shown that premature human infants provided with minimal enteral nutrition have 
lower rates of NEC than those maintained NPO42.  This could be due to the fact that the 
microbiome is vital in protecting the intestines and enteral nutrition contributes to timely 
acquisition of commensal microbiota. Thus, a lack of enteral feeding can contribute to a 
dysbiosis that can increase NEC susceptibility43.  
There are potential limitations to this study. First and foremost, the AP lambs were only 
supported on the device for 7 days. It might take more than 7 days for changes to occur to the 
bowel mucosa. This is could be another explanation for why CD, VH, and CD:VH ratios were 
similar between the AP, ETC, and LTC groups. Furthermore, the administration of vasopressor 
medications was not consistent across all the lambs in the AP group. Earlier experiments had a 
lower threshold for starting these medications, but currently, these medications are avoided 
unless absolutely necessary. Thus it is possible that future AP experiments (on the current 
vasopressor protocol) will show less bowel injury. Lastly, this study only focused on changes in 
bowel structure as cause for injury even though the importance of the microbiota in maintaining 
a healthy GI tract and providing protection against injury and inflammation is very well known8.  
Nevertheless, overall it seems as though the AP is doing what it is intended to do. The 
data from this study supports that premature lambs on the AP show intestinal structure and 
development similar to the in-utero structure and development of the tissue control lambs and 
that AP lambs and show similar responses to inflammation and injury as term infants. However, 
despite this, a number of the AP supported lambs have succumbed to GI related complications 
including suspected NEC. This study showed that these complications aren't likely due to 
structural or developmental issues, thus future studies on AP lambs will focus on investigating 
the gut microbiome. Comparisons can be done between AP lambs showing evidence of GI 
compromise or that died of supposed NEC and those that were electively sacrificed.  
During necropsy of all AP and tissue control lambs, small sections of the small intestine 
were obtained and frozen for future analysis. I propose a slow thawing of this tissue, followed by 
homogenization and PCR to replicate the 16S rRNA gene. By doing this, only the bacterial cells 
will be amplified. The PCR product can then be sent off for next generation sequencing. This 
will allow for identification of the bacterial species that colonized the small intestines of the AP 
lambs. These bacterial profiles can be compared between lambs electively sacrificed and those 
suspected of having GI complications. Furthermore, a study can be done comparing these 
microbiological profiles from those obtained from stool samples from term lambs. NEC 
disproportionately affects premature infants, so maybe this can elucidate whether there are 
differences in the microbiota of premature vs. term infants. If so, these profiles could provide 
valuable information about bacteria associated with NEC.     
 
CONCLUSION 
 This study supports the hypothesis that intestinal architecture would be preserved during 
AP support and that injury and injury response of AP supported lambs would be comparable to 
tissue controls. The AP can provide revolutionary support to extremely premature newborns, 
allowing them to continue normal organ growth and development even after birth in a simulated 
intra-uterine environment. This device will be promoted both as a way to decrease morbidity and 
mortality and to increase quality of life for extremely premature newborns. As a result, thorough 
investigation of its effects on the various organ systems needs to be done. The analysis of the 
effect of the AP on intestinal growth and development has been, so far, positive.  
 
ACKNOWLEDGEMENTS 
 Huge thank you to Dr. Gary Huffnagle for being my thesis advisor, helping me through 
this process, reading multiple drafts of my work, and responding to all my nitpicking emails. 
Also thank you to Drs. Jennifer McLeod, Alvaro Rojas Peña, and Robert Bartlett for allowing me 
to work on this project and use ECMO Lab resources. Thanks also to Dr. Joel Greenson for all 
his guidance in teaching me about GI histology and patience in responding to the plethora of 
emails I sent asking if my methodology was correct. Finally, thank you to Dr. Mika Lavaque-



















Fig. 129. Schematic of the artificial placenta (AP) circuit in a premature lamb model 
demonstrating the cannulated lamb for VV ELCS, collapsible-tubing roller pump (M-Pump), and 
oxygenator/heat exchanger.  Ao: Aorta; IVC: Inferior Vena Cava; DV: Ductus Venosus; RA: 
Right Atrium; SVC: Superior Vena Cava; IJV: Internal Jugular Vein. Thanks to Dr. Alvaro 











Figure 2. GI Structure: Crypt Depth and Villus Height 
 
Fig. 229. Representative histological images and graph comparing GI morphology of all groups.  
(A) ETC [H&E Stain]; (B) AP [H&E Stain]; (C) LTC [H&E Stain]; H&E, 200x magnification; 
(D) Graph demonstrating no significant difference when comparing Crypt Depth (CD), Villus 
Height (VH), or CD:VH Ratio of all groups.  ETC: Early Tissue Control; AP: Artificial Placenta; 
LTC: Late Tissue Control. P-values calculated by ANOVA.  * Indicates significance p<0.05. 
Thanks to Dr. Jennifer McLeod for assistance in making the graph schematic (D).  
 
 
Figure 3. GI Enterocyte Proliferation 
 
Fig. 329. Representative histological images and graph comparing enterocyte proliferation of all 
groups.  (A) ETC [Ki-67 Stain]; (B) AP [Ki-67 Stain]; (C) LTC [Ki-67 Stain]; Ki-67, 200x 
magnification; (D) Graph demonstrating significantly increased proliferation in enterocytes of 
the AP group compared to both ETC and LTC groups.  ETC: Early Tissue Control; AP: 
Artificial Placenta; LTC: Late Tissue Control.  P-values calculated by ANOVA.  * Indicates 
significance p<0.05. Thanks to Dr. Jennifer McLeod for assistance in making the graph 
schematic (D). 
 
Table 1. Presence of GI Mucosal Injury 
  AP (n=5) ETC (n=5) LTC (n=5) p-value 




















































Table 129. Numbers represent number of samples manifesting injury type within specified region 
(out of n=5).  AP: Artificial Placenta; ETC: Early Tissue Control; LTC: Late Tissue Control; TI: 
Terminal ileum; Jej: jejunum; Prox: proximal; p-values calculated by Chi-square.  * Indicates 
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